RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas

By Serrano César   Romagosa Cleofé   Hernández-Losa Javier   Simonetti Sara   Valverde Claudia   Moliné Teresa   Somoza Rosa   Pérez Manuel   Vélez Roberto   Vergés Ramona   Domínguez Rosa   Carles Joan   Ramón y Cajal Santiago  

Cancer, Vol. 122, Iss. 1, 2016-01 ,pp. : 99-107

Blackwell Publishing

Access to resources Recommend Favorite

Network Pharmacology Strategies Toward Multi-Target Anticancer Therapies: From Computational Models to Experimental Design Principles

By  

Current Pharmaceutical Design, Vol. 20, Iss. 1, 2014-01 ,pp. : 23-36

Bentham Science Publishers

Access to resources Recommend Favorite

Initial Design and Synthesis of Conformationally Restricted and Pharmacophore-Based Scaffold Hopping Analogs of a Ras Pathway Modulator and Evaluation of Their MAPK Inhibitory Activities

By  

Letters in Drug Design & Discovery, Vol. 3, Iss. 1, 2006-02 ,pp. : 44-48

Bentham Science Publishers

Access to resources Recommend Favorite

Perspective on Multi-Target Antiplatelet Therapies: High Content Phenotypic Screening as an Unbiased Source of Novel Polypharmacological Strategies

By  

Mini Reviews in Medicinal Chemistry, Vol. 15, Iss. 8, 2015-06 ,pp. : 622-629

Bentham Science Publishers

Access to resources Recommend Favorite

Strategies for Overcoming Inherent and Acquired Resistance to EGFR Inhibitors by Targeting Downstream Effectors in the RAS/PI3K Pathway

By  

Current Cancer Drug Targets, Vol. 10, Iss. 8, 2010-12 ,pp. : 824-833

Bentham Science Publishers

Access to resources Recommend Favorite